Gliclazide
Yes
No
Standard Drug List
Active ingredient: Gliclazide
General information
Subsidy Information and Financing Scheme
Drug Guidance for Subsidy
03/05/2017 Gliclazide for the treatment of type 2 diabetes mellitus
Following an evaluation of gliclazide for the treatment of type 2 diabetes mellitus, gliclazide 80mg immediate release tablet is recommended for listing on the MOH Standard Drug List (SDL) by the MOH Drug Advisory Committee in view of its better safety profile compared to other sulfonylureas and low annual cost of subsidy.
[R] This recommendation means that subsidies will apply to gliclazide 80mg immediate release tablet for the indications registered in Singapore:
Non-insulin-dependent diabetes, in association with an adapted diet, in cases where dietary measures alone provide inadequate control of blood glucose levels.
[NR] Gliclazide 60mg modified release tablet is not recommended for listing on the MOH Standard Drug List in view that there is no difference in clinical outcomes for the modified release tablet compared with the immediate release tablet to justify the significant cost difference between the two preparations.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Tablet 80 mg |
|
Tablet, Film Coated, Extended Release 60 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.
